Abstract
The PML/RAR alpha fusion gene resulting from the t (15;17) translocation is a specific marker for acute promyelocytic leukemia (APL). We examined bone marrow cells by reverse transcriptase-polymerase chain reaction (RT-PCR) to detect residual PML/RAR alpha mRNA-containing cells following treatment with all-trans retinoic acid (ATRA) and cytotoxic chemotherapy in a patient with APL. This RT-PCR assay can detect one leukemic cell in 10(2) normal cells in vitro. We show that PML/RAR alpha mRNA was still detectable despite clinical remission following ATRA treatment, but undetectable following consolidation with chemotherapy. These data show that this technique is useful for the identification of minimal residual disease in patients with APL and that cytotoxic chemotherapy following ATRA therapy is required for the elimination of APL cells.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Base Sequence
-
Biomarkers, Tumor / genetics*
-
Female
-
Humans
-
Leukemia, Promyelocytic, Acute / diagnosis
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Leukemia, Promyelocytic, Acute / genetics*
-
Leukocytes, Mononuclear
-
Middle Aged
-
Molecular Sequence Data
-
Neoplasm Proteins*
-
Nuclear Proteins*
-
Polymerase Chain Reaction / methods
-
Promyelocytic Leukemia Protein
-
RNA, Messenger / genetics
-
RNA, Neoplasm / genetics
-
Receptors, Retinoic Acid / genetics*
-
Retinoic Acid Receptor alpha
-
Transcription Factors / genetics*
-
Tretinoin / therapeutic use*
-
Tumor Suppressor Proteins
Substances
-
Biomarkers, Tumor
-
Neoplasm Proteins
-
Nuclear Proteins
-
Promyelocytic Leukemia Protein
-
RARA protein, human
-
RNA, Messenger
-
RNA, Neoplasm
-
Receptors, Retinoic Acid
-
Retinoic Acid Receptor alpha
-
Transcription Factors
-
Tumor Suppressor Proteins
-
PML protein, human
-
Tretinoin